The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Germany defends AstraZeneca pivot as key to speeding vaccinations

Fri, 07th May 2021 09:54

* All adults now free to get AZ shot, on doctor's advice

* Gap between doses can be as little as 4 weeks

* Experts warn on reduced efficacy with shorter gap

* Third wave of pandemic "appears to be broken" - minister
(Recasts to lead on AstraZeneca shift)

By Douglas Busvine and Paul Carrel

BERLIN, May 7 (Reuters) - Health Minister Jens Spahn on
Friday defended another U-turn by Germany on the AstraZeneca
vaccine, saying making it available to all adults who
want it would protect more people against COVID-19 more quickly.

Spahn announced late on Thursday that Germany would make
AstraZeneca available to all adults, subject to consulting a
doctor, and allow people to get a second shot as soon as four
weeks after the first.

The move comes with an eye to the summer holidays and
coincides with the rapid passage of legislation that would free
those fully vaccinated from social distancing measures imposed
to fight the pandemic.

Germany had previously limited the shot from the
Anglo-Swedish drugmaker to people over 60 after post-vaccination
monitoring found rare - and sometimes fatal - cases of blood
clotting, with younger women disproportionately affected.

Before that, its vaccine oversight body had said the shot
could not be given to the elderly because of a lack of data from
clinical trials.

With 70% of older people now inoculated and Germany's
vaccination drive gaining momentum, Spahn said the latest step
on AstraZeneca would offer a vaccination option to people who
would otherwise have to wait.

"We are convinced this offer is attractive for those who
would otherwise not get vaccinated so quickly," Spahn told a
news conference, adding that 1 million AstraZeneca doses would
be sent to doctors' practices next week.

THE SOONER, THE WORSE?

The decision by the federal government follows moves by
several German states to make AstraZeneca more widely available
and comes as the pace of giving shots of mainstay vaccines from
BioNTech/Pfizer and Moderna picks up.

The share of the population that has received a first
vaccine shot has reached 31.5%, with 900,000 getting a dose on
Thursday, putting Germany "in the fast lane" by international
standards, said Spahn.

He said the third wave of the coronavirus pandemic "appears
to be broken" while Germany's top public health official, Lothar
Wieler, said infections were falling across all age groups
thanks to social distancing and the progress on vaccinations.

Confirmed cases rose by 18,485 on Friday, with 284
fatalities, while the seven-day incidence fell to 125.7 cases
per 100,000 people, data from the Robert Koch Institute showed.

However, experts criticised the decision to allow people to
receive the AstraZeneca vaccine at shorter intervals, saying
studies had shown its efficacy to be only around 55% with a
four-week gap and 80% with a 12-week delay to the second shot.

"We have to make it clear that if people shorten the gap
between AstraZeneca doses to enjoy greater freedom of movement
sooner, they are doing so at the cost of their immune
protection," said Carsten Watzl, professor of immunology at the
Dortmund Technical University.

Spahn said this was a decision that people should take with
proper advice, a view seconded by Robert Koch Institute head
Wieler.

"We know that the longer the gap before the second shot the
better the protection," Wieler said. "This is an informed
decision people can take in consultation with their doctors."
(Writing by Douglas Busvine
Editing by Gareth Jones)

More News
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.